Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

J Overman

Showing results (201-210 of 265) with videos related to

Pageof 27
Sort By:
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|March 11, 2017
Dual Inhibition of EGFR and c-Src by Cetuximab and Dasatinib Combined with FOLFOX Chemotherapy in Patients with Metastatic Colorectal CancerChristine M Parseghian, Nila U Parikh, Ji Yuan Wu, et al.
European Journal of Cancer (Oxford, England : 1990)|July 21, 2025
Prognostic impact of the BRAF V600E mutation in patients with MSI-high metastatic colorectal cancer treated with immune checkpoint inhibitorsClaire Gallois, Margherita Ambrosini, Sara Lonardi, et al.
Cancer Discovery|October 13, 2016
Phase IB Study of Vemurafenib in Combination with Irinotecan and Cetuximab in Patients with Metastatic Colorectal Cancer with BRAFV600E MutationDavid S Hong, Van K Morris, Badi El Osta, et al.
BMC Cancer|October 18, 2015
Retreatment with anti-EGFR based therapies in metastatic colorectal cancer: impact of intervening time interval and prior anti-EGFR responseX Liu, G C George, A M Tsimberidou, et al.
JAMA Network Open|June 1, 2023
Efficacy of Systemic Chemotherapy in Patients With Low-grade Mucinous Appendiceal Adenocarcinoma: A Randomized Crossover TrialJohn Paul Shen, Abdelrahman M Yousef, Fadl A Zeineddine, et al.
Physiology & Behavior|April 29, 2022
Reproductive hormone levels, androgen receptor CAG repeat length and their longitudinal relationships with decline in cognitive subdomains in men: The European Male Ageing StudyMargot J Overman, Neil Pendleton, Terence W O'Neill, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|January 21, 2017
High prevalence of mutant KRAS in circulating exosome-derived DNA from early-stage pancreatic cancer patientsK Allenson, J Castillo, F A San Lucas, et al.
Cancer Medicine|July 12, 2021
Antibiotic use influences outcomes in advanced pancreatic adenocarcinoma patientsChirayu Mohindroo, Merve Hasanov, Jane E Rogers, et al.
The Oncologist|July 17, 2024
Clinical and molecular characteristics of patients with brain metastasis secondary to pancreatic ductal adenocarcinomaMahmoud Yousef, Mark W Hurd, Abdelrahman Yousef, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|November 29, 2017
Classifying Colorectal Cancer by Tumor Location Rather than Sidedness Highlights a Continuum in Mutation Profiles and Consensus Molecular SubtypesJonathan M Loree, Allan A L Pereira, Michael Lam, et al.
Pageof 27

Showing results (201-210 of 265) with videos related to

Sort By:
Pageof 27
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|March 11, 2017
Dual Inhibition of EGFR and c-Src by Cetuximab and Dasatinib Combined with FOLFOX Chemotherapy in Patients with Metastatic Colorectal CancerChristine M Parseghian, Nila U Parikh, Ji Yuan Wu, et al.
European Journal of Cancer (Oxford, England : 1990)|July 21, 2025
Prognostic impact of the BRAF V600E mutation in patients with MSI-high metastatic colorectal cancer treated with immune checkpoint inhibitorsClaire Gallois, Margherita Ambrosini, Sara Lonardi, et al.
Cancer Discovery|October 13, 2016
Phase IB Study of Vemurafenib in Combination with Irinotecan and Cetuximab in Patients with Metastatic Colorectal Cancer with BRAFV600E MutationDavid S Hong, Van K Morris, Badi El Osta, et al.
BMC Cancer|October 18, 2015
Retreatment with anti-EGFR based therapies in metastatic colorectal cancer: impact of intervening time interval and prior anti-EGFR responseX Liu, G C George, A M Tsimberidou, et al.
JAMA Network Open|June 1, 2023
Efficacy of Systemic Chemotherapy in Patients With Low-grade Mucinous Appendiceal Adenocarcinoma: A Randomized Crossover TrialJohn Paul Shen, Abdelrahman M Yousef, Fadl A Zeineddine, et al.
Physiology & Behavior|April 29, 2022
Reproductive hormone levels, androgen receptor CAG repeat length and their longitudinal relationships with decline in cognitive subdomains in men: The European Male Ageing StudyMargot J Overman, Neil Pendleton, Terence W O'Neill, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|January 21, 2017
High prevalence of mutant KRAS in circulating exosome-derived DNA from early-stage pancreatic cancer patientsK Allenson, J Castillo, F A San Lucas, et al.
Cancer Medicine|July 12, 2021
Antibiotic use influences outcomes in advanced pancreatic adenocarcinoma patientsChirayu Mohindroo, Merve Hasanov, Jane E Rogers, et al.
The Oncologist|July 17, 2024
Clinical and molecular characteristics of patients with brain metastasis secondary to pancreatic ductal adenocarcinomaMahmoud Yousef, Mark W Hurd, Abdelrahman Yousef, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|November 29, 2017
Classifying Colorectal Cancer by Tumor Location Rather than Sidedness Highlights a Continuum in Mutation Profiles and Consensus Molecular SubtypesJonathan M Loree, Allan A L Pereira, Michael Lam, et al.
Pageof 27